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recurrence avoided is €82 in the 5 years time horizon and the
open mesh is the dominant option in the 15 years time horizon
from a hospital perspective. Results in the probability sensitivity
analysis are very similar to deterministic analysis. CONCLU-
SION: Findings suggest open mesh hernia repair method as a
very cost effective therapy from both hospitals and payers per-
spectives for the inguinal hernia treatment in Slovakia.
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OBJECTIVE: Operating rooms (OR) are an expensive hospital
resource. As a new selective reversal binding agent, sugammadex
has been shown in clinical trials to reduce reversal time (time
from reversal agent administration to full recovery) among
patients receiving selected steroidal neuromuscular-blocking
agents (NMBAs). Our goal was to develop a hospital efﬁciency
model to assess the potential impact of sugammadex adoption on
OR time. METHODS: A deterministic model was developed to
estimate potential time savings associated with sugammadex
adoption for the U.S. setting. Model inputs included surgical
caseloads, utilization rates of NMBAs and reversal strategies, OR
time components, and OR labor costs. The effects of reversal
strategies on reversal time were evaluated using clinical trial data.
Other model inputs were estimated using published literature
and analyses of secondary hospital databases. OR time saved was
deﬁned as the difference in minutes required for all procedures
performed per day in one OR before and after the introduction of
sugammadex. Estimates of savings in OR staff costs (including
OR nurse, OR technician, and certiﬁed registered nurse anesthe-
tist) were generated under alternative assumptions about the
likelihood that overtime is paid. Sensitivity analyses were per-
formed on key model assumptions. RESULTS: In the base-case
scenario, OR time saved by sugammadex was estimated to be
25 minutes per OR day or 612 hours annually in a typical US
hospital with 6 ORs. Associated annual cost savings were esti-
mated to range from $32,035 (25% of days involve overtime) to
$96,105 (75% of days involve overtime). Findings also varied
with the assumed adoption rate of sugammadex and hourly OR
staff salaries. CONCLUSION: Sugammadex may save OR time
and associated costs for U.S. hospitals, primarily by reducing
overtime pay. The net ﬁnancial beneﬁt of sugammadex will
depend on its cost and its adoption rate in clinical practice.
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OBJECTIVE: Deep vein thrombosis (DVT) and pulmonary
embolism (PE), collectively known as venous thromboembolism
(VTE), are well-known complications of total knee or hip
arthroplasty (TKA and THA). This study examined the eco-
nomic burden of VTE in arthroplasty surgeries from a US hos-
pital perspective. METHODS: Patients at least 18 years old
undergoing TKA and THA from January 1, 2002 to December
30, 2006 were extracted from a large, nationwide inpatient
database. Rates of events, length of hospital stay, inpatient costs
and reimbursed amounts (available for a small subset that could
be linked to managed care data) were evaluated. Multivariate
analyses were conducted on hospital costs to adjust for differ-
ences in demographic and clinical characteristics. RESULTS:
Out of 259,524 hip and knee surgeries (mean age of 67 years),
1.0% of patients diagnosed with VTE during hospitalization
(0.6% DVT only and 0.4% PE [with or without DVT]). Com-
pared to patients without VTE, mean length of stay (LOS) for
those with VTE was twice as long (8 vs. 4, p < 0.0001) and
hospital costs were 48.0% higher ($20,850 vs. $14,092,
p < 0.0001). Within the limited subset that had linked managed
care claims data (n = 5002), mean cost of patients with VTE
was 23.5% higher ($16,877 vs. $13,662, p < 0.0023); however,
the amount reimbursed was on average 6.4% higher ($14,121
vs. $13,272, p = 0.77). After multivariate adjustment, DVT
increased costs by $1421 following TKA and $3950 following
THA; PE increased costs by $2862 following TKA and $4355
following THA (p < 0.0001 for all). CONCLUSION: Experi-
encing VTE complications substantially adds to the costs of
TKA or THA. The increased hospital costs of patients with VTE
did not appear to be adequately reimbursed. The overall eco-
nomic impact of implementing prophylaxis to prevent VTE
events can be projected.
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OBJECTIVE: The objective of this project was to review pub-
lished studies on quality of life (QoL) in animals. METHODS:
An electronic search in EMBASE including MEDLINE using
the key words “quality of life” and “animals” resulted in 1588
articles. Inclusion criteria for review was study on QoL, exclu-
sion criteria were case studies with n < 3, and studies in labora-
tory animals as proxy for humans. RESULTS: A total of 48
studies were included for review, of which 40 were performed in
dogs. The aim of nine studies was the development and valida-
tion of a questionnaire, three studies provided a checklist or
background information on QoL in animals. In the remaining 36
studies QoL was assessed as outcome measure in speciﬁc diseases
or treatments; however 30 of these studies were uncontrolled.
Previously developed, used or validated questionnaires were
included in only 3 studies. In 23 studies assessment of QoL was
limited to one single question, addressed to the owners. In 30 of
the 36 studies the evaluation of QoL was performed only at one
time point after the start of an intervention, of which 3 studies
retrospectively evaluated a baseline value. In 19 studies, all or
part of the animals were already dead at the time of assessment.
In 19 of the 30 uncontrolled studies QoL was rated as good to
excellent (or equivalent in scores) in >50% of the animals, even
in studies on severe conditions such as cancer or chemotherapy.
CONCLUSION: Most of the studies assessing QoL as outcome
used unvalidated questionnaires and included only one single
question addressed to the owners. It is questionable whether the
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multidimensionality of QoL can be assessed properly this way;
especially in this speciﬁc situation where the owners are proxy
reporters but also responsible for the well-being of the animal
and therefore likely to be biased.
HEALTH CARE INTERVENTIONS—Health Care Use &
Policy Studies
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OBJECTIVE: A European STARR registry was set-up to deter-
mine the short-term safety and effectiveness of the STARR
procedure for obstructed defaecation syndrome. METHODS:
STARR registries in Italy, Germany and the UK were designed
with a web-based interface to allow pooling of results for com-
bined analysis. Recruitment commenced in January 2006. Data
collection included a symptom severity score (SSS), obstructed
defaecation score (ODS), Cleveland clinic incontinence score,
symptom-speciﬁc (PAC-QoL) and generic (ED-5Q utility and
VAS) QoL score. All complications were recorded. Data collec-
tion was performed at baseline, 6 weeks, and 6 and 12 months.
RESULTS: A total of 1456 patients were recruited and eligible
for analysis. There were 214 (14.7%) male patients. The mean
age was 54 yrs (range: 17–92). Mean operative time was 44mins
(range: 15–210). Average length of stay was 3 days (range:1–36).
By September 2007, 698 (48%) and 422 (29%) were eligible for
analysis at 6 and 12 months. respectively. A signiﬁcant symptom-
atic improvement was seen between baseline and 6 months and
maintained at 12 months (SSS: baseline 24.1 (95%CI: 23.8,24.4)
v’s 12 months 12.5 (95%CI: 12.1,12.9), p < 0.001; ODS: base-
line 15.3 (95%CI: 14.9,15.6) v’s 12 months 5.8 (95%CI:
4.8,6.7), p < 0.001. This was reﬂected in a signiﬁcant improve-
ment in both PAC-QoL and ED-5Q QoL scores at both 6 and
12 months. Incontinence scores improved from 3.1 (95%CI:
2.9,3.3) at baseline to 2.9 (95%CI: 2.1,2.7) at 6 months and
1.9 (95%CI: 1.5,2.2) at 12 months (p < 0.001). 457 minor and
major complications were reported, of which the most frequent
were: unexpected pain (7.7%), urinary retention (6.8%), bleed-
ing (4.5%), stapled line complications (3.2%), sepsis (1.4%),
incontinence (1.3%). Postoperative defaecatory urgency was
reported in 17% of patients. There was no mortality. CONCLU-
SION: STARR for ODS is safe,effective and signiﬁcant improve-
ment in QoL.
INDIVIDUAL’S HEALTH—Clinical Outcomes Studies
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OBJECTIVE: As part of a broader analysis on aging in the
community, the purpose is to perform a literature review to assess
the effectiveness of interventions designed to prevent falls and
fall-related injuries in community-dwelling elderly individuals.
METHODS: A search was performed in OVID MEDLINE,
MEDLINE In-Process and Other Non-Indexed Citations,
EMBASE, CINAHL, Cochrane Library, and INAHTA/NHS EED
between January 2000 and September 2007. Furthermore, all
studies included in a Cochrane review published in 2003 were
considered for inclusion. Studies were included if they were con-
trolled trials in a population of community dwelling elderly and
examined falls or fall-related injuries as an outcome. RESULTS:
Fifty-nine studies were identiﬁed investigating the effectiveness of
nine interventions. A meta-analysis found that exercise programs
effectively reduced falls if they were 6 months or longer in dura-
tion (RR = 0.84 [95% CI: 0.76–0.93]) or were offered to the
general population and not a high risk group (RR = 0.79 [0.70–
0.90]). Environmental modiﬁcations were effective in individuals
with a history of falls (RR = 0.66 [0.54–0.81]), and a gait
stabilizing device for outdoor winter use effectively reduced
falls (RR = 0.43 [0.29–0.64]) and injurious falls (RR = 0.10
[0.01–0.74]). Although neither hormone replacement therapy or
vitamin D alone reduced falls or injuries, vitamin D plus calcium
supplementation resulted in a reduction in the number of falls
(RR = 0.83 [0.73–0.95]) and fractures (RR = 0.60 [0.39, 0.94]).
Multifactorial interventions were only marginally effective in
reducing falls in a high risk population (RR = 0.87 [0.76–1.01]),
and there was no evidence that vision interventions or hip pro-
tectors were effective. CONCLUSION: Several interventions
were identiﬁed which reduce the risk of falls and fall-related
injuries in community-dwelling elderly, however special con-
sideration must be given to the intervention duration and
population risk proﬁle when determining the most appropriate
interventions to implement. An economic analysis that informs
investment decisions to maximize the impact of reducing falls is
currently underway.
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OBJECTIVE: Contraceptive efﬁcacy depends both on patient
compliance and the characteristics of the method used. Efﬁcacy
rates can thus vary across different populations, particularly in
women employing user-dependent methods (i.e., oral, condoms).
This study measured the contraceptive failure rates in a Medicaid
and a non-Medicaid population and evaluated the efﬁcacy
variance between the two groups. METHODS: Monthly
contraceptive-use histories were constructed for all women using
data from the 2002 National Survey of Family Growth (NSFG
VI). Contraceptive use was deﬁned by ﬁrst contraception method
mentioned in the survey. Poly-modal use was not deﬁned.
Women were classiﬁed as Medicaid enrollees if they reported
having Medicaid coverage in the 12 months prior to the survey,
or reported Medicaid payment for services. The ﬁnal dataset
included 1208 Medicaid-enrolled women and 6435 non-
Medicaid enrolled women. Pregnancy rates were calculated each
month and then annualized for women using user-dependent
methods (oral contraceptives [OC], condom) or non-daily
methods (IUD, injected, implanted birth control). RESULTS:
Average annual contraceptive failure rates for Medicaid vs. non-
Medicaid women were: oral pill—1.15% vs 0.13% (p = 0.0051);
condom—2.05% vs. 0.55% (p = 0.0015); IUD—0.52% vs.
0.16% (p = 0.5156); injected or implanted—0.27% vs. 0.13%
(p = 0.3940). OC failure rate was nearly 9-times higher in the
Medicaid population than in the non-Medicaid population. Fail-
ures rates for IUD, injectables and implants were also higher but
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